Alcon Research, Ltd.

Alcon Universal Ltd.

Arrowhead Pharmaceuticals, Inc.

Alcon, Inc.

Alcon Laboratories, Inc.

Other

Arrowhead Research Corporation

John M. Yanni

Steven T. Miller

Ltd. Alcon Manufacturing

Jon E. Chatterton

Daniel A. Gamache

Steven T Miller

John M Yanni

Daniel A Gamache

Jon E Chatterton

Mark R Hellberg

Zixia Feng

Andrew Rusinko

Diane Michelle Senchyna

John E Chatterton

RNA interference is provided for inhibition of phosphodiesterase type 4 mRNA expression for treating patients with a cAMP-related ocular disorder. Phosphodiesterase type 4 mRNA targets include mRNA for 4A, 4B, 4C, and 4D phosphodiesterase isoforms.

RNAi-mediated inhibition of phosphodiesterase type 4 for treatment of CAMP-related ocular disorders

RNA interference is provided for inhibition of histamine receptor H1 mRNA expression, in particular, for treating patients having an HRH1-related condition or at risk of developing an HRH1-related condition such as allergic conjunctivitis, ocular inflammation, dermatitis, rhinitis, asthma, or allergy.

RNAi-mediated inhibition of histamine receptor H1-related conditions

RNAi-mediated inhibition of phosphodiesterase type 4 for treatment of cAMP-related ocular disorders

RNA interference is provided for inhibition of tumor necrosis factor &#x3b1; (TNF&#x3b1;) by silencing TNF&#x3b1; cell surface receptor TNF receptor-1 (TNFR1) mRNA expression, or by silencing TNF&#x3b1; converting enzyme (TACE/ADAM17) mRNA expression. Silencing such TNF&#x3b1; targets, in particular, is useful for treating patients having a TNF&#x3b1;-related condition or at risk of developing a TNF&#x3b1;-related condition such as the ocular conditions dry eye, allergic conjunctivitis, or ocular inflammation, or such as dermatitis, rhinitis, or asthma, for example.

RNAi-mediated inhibition of tumor necrosis factor &#x3b1;-related conditions

RNA interference is provided for inhibition of spleen tyrosine kinase (Syk) mRNA expression, in particular, for treating patients having a Syk-related inflammatory condition or at risk of developing a Syk-related inflammatory condition such as allergic conjunctivitis, ocular inflammation, dermatitis, rhinitis, asthma, allergy, or mast-cell disease.

RNAi-mediated inhibition of spleen tyrosine kinase-related inflammatory conditions

Methods for treating an allergic or inflammatory disease or other Syk-mediated disease or Syk-mediated condition characterized by administering a composition which contains a therapeutically effective amount of a 3,6-substituted imidazol[1,2-b]pyridazine compound.

3,6-substituted imidazol[1,2-b]pyridazine analogs for treating allergic and inflammatory diseases

Methods for treating an allergic or inflammatory disease or other Syk-mediated disease or Syk-mediated condition characterized by administering a composition which contains a therapeutically effective amount of a 5-substituted 2-aminopyridine compound.

5-substituted 2-aminopyridine analogs for treating allergic and inflammatory diseases

Growing community of inventors

Arlington, TX, United States of America

Steven T Miller